Unknown PHASE2 INTERVENTIONAL 2-arm NCT01466543

Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity (SMCZN01)

Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects

Sponsor: Dong-A Pharmaceutical Co., Ltd.

Conditions Subcortical Vascular Dementia Vascular Dementia

Interventions Placebo Zydena (Udenafil)

Updated 6 times since 2017 Last updated: Nov 7, 2011 Started: Nov 30, 2011 Primary completion: Mar 31, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01466543, this PHASE2 trial focuses on Subcortical Vascular Dementia and Vascular Dementia and remains ongoing. Sponsored by Dong-A Pharmaceutical Co., Ltd., it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A Pharmaceutical Co., Ltd.
Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea